DIRS.INFO The most relevant business & tech news

☆ Biden proposes requiring Medicare, Medicaid to cover weight loss drugs
▼ + stars: | 2024-11-26 | by ( Evan Bush | Evan Bush Is A Science Reporter For Nbc News. | ) www.nbcnews.com time to read: +3 min

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for patients seeking to treat obesity. Today, a month's supply of weight loss drugs can cost $1,000 or more, according to estimates from a White House official. About 72 million Americans were enrolled in Medicaid as of July, according to the Centers for Medicare & Medicaid Services. Research suggests there are significant disparities in who receives weight loss drugs. Weight loss drugs like Wegovy are injectable medications of semaglutide.

Persons: Dr, Laure DeMattia Organizations: Biden, White, Centers for Disease Control, White House, Centers, Medicare, Medicaid Services, Kaiser Family Foundation . Research, NBC News, Health Affairs Locations: Norman , Oklahoma, U.S

☆ Biden administration plans to expand coverage of GLP-1 drugs for Americans with Medicare & Medicaid
▼ + stars: | 2024-11-26 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBiden administration plans to expand coverage of GLP-1 drugs for Americans with Medicare & MedicaidCNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs for Americans with Medicare and Medicaid.

Persons: Bertha Coombs Organizations: Biden, Medicare

☆ Medicare, Medicaid: 7.4 million Americans could gain coverage for anti-obesity drugs under Biden proposal
▼ + stars: | 2024-11-26 | by ( Tami Luhby | ) edition.cnn.com time to read: +4 min

CNN —Millions more senior citizens and lower-income Americans could obtain coverage for costly anti-obesity drugs under a proposal being unveiled Tuesday by the Biden administration. Some Medicare enrollees could see their out-of-pocket costs drop by as much as 95%. The incoming Trump administration may not view expanding coverage of anti-obesity drugs as favorably. About 3.6 million Medicare enrollees with cardiovascular disease could be newly eligible for Wegovy, according to a KFF analysis released in April. Not all job-based health insurance plans cover anti-obesity medications, though larger employers are more likely to offer the benefit.

Persons: Biden, It’s, Joe Biden, Trump, Robert F, Kennedy Jr, Donald Trump, Dr, Mehmet Oz, don’t Organizations: CNN, Medicare, Department of Health, Human Services, RFK Jr, Fox, Services, Trump, Medicare enrollees, Food and Drug Administration, Congressional, Survey Locations: That’s, KFF

☆ Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
▼ + stars: | 2024-11-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Amgen on Tuesday said its experimental weight loss injection helped patients with obesity lose up to 20% of their weight on average after a year in a critical mid-stage trial, as the company races to join the booming obesity drug market. The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients, which indicates the potential for further weight loss beyond 52 weeks. That could boost Amgen's odds of winning a slice of the weight loss drug market, which some analysts forecast could be worth $150 billion a year by the early 2030s. That's unlike Eli Lilly's obesity drug, Zepbound, which activates both GIP and GLP-1.

Persons: Amgen, MariTide, Eli Lilly, Robert Bradway, Jay Bradner, Nordisk's Wegovy, Eli Lilly's Zepbound, Zepbound, Eli, Wegovy, Bradner Organizations: Novo Nordisk, Nordisk's Locations: Amgen, Thousand Oaks , California

☆ Thanksgiving on Ozempic: 5 rules for eating and dosing during the holidays
▼ + stars: | 2024-11-26 | by ( ) www.businessinsider.com time to read: +4 min

Popular weight-loss drugs shouldn't keep you from enjoying the holidays, according to a doctor. GLP-1 medications like semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have been a game-changer for weight management in recent years. To stay on track and enjoy the season, avoid these misunderstandings about GLP-1 medications that arise around food-related holidays. Don't feel like you're going to miss out on holiday funTaking a GLP-1 over the holidays won't prevent you from enjoying the festivities. It doesn't mean that you're not going to want to eat turkey and the foods you'll have over the holidays.

Persons: shouldn't, Ozempic, Caroline Apovian, Apovian, it's Organizations: Center, Weight Management, Wellness, Brigham, Women's Locations: GLP

☆ We're adding this Bullpen stock to the portfolio and adding to a long-held position
▼ + stars: | 2024-11-25 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

In addition, we will buy 5 shares of Eli Lilly at roughly $750. Separately, we can finally add to our position in Eli Lilly. We want to buy into this correction because Eli Lilly shares are back trading at an appealing valuation relative to its growth rate. If you look out to 2026, Lilly shares are trading at roughly 25 times. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Eli Lilly, Jim Cramer's, Bristol Myers, Chris Boerner, Karuna, Robert F, Kennedy Jr, Lilly, Jim Cramer, Jim Organizations: Myers Squibb, BMY, pharma, Karuna Therapeutics, FDA, JPMorgan, Bristol, of Health, Human Services, Jim Cramer's Charitable, CNBC, Traders, New York Stock Exchange, NYSE Locations: Bristol, New Jersey, U.S, New York City

☆ The New York Times Presents: ‘Weight of the World’ on Ozempic’s Rise
▼ + stars: | 2024-11-22 | by ( ) www.nytimes.com time to read: +1 min

‘Weight of the World’Producer/Director Esther Dere and Nicole RittenmeyerCo-Producer Leah VarjacquesProducer/Reporter Dani BlumProducer Rachel AbramsWatch our new documentary on FX and Hulu starting Friday, Nov. 22, at 10 p.m. Eastern. The ascent of GLP-1 medications, such as Ozempic, has brought about a transformation within the weight-loss industry and beyond, reshaping societal views on health and body image. Originally developed to manage diabetes, these drugs have become associated with rapid weight reduction, capturing public interest thanks to rumored endorsements from high-profile figures like Oprah Winfrey and Elon Musk. “Weight of the World” dives into this pivotal moment, following the journeys of three individuals as they navigate the complexities of using GLP-1 medications. Through expert commentary from medical professionals, dietitians and cultural critics, the film looks at this evolving landscape, and it investigates the societal obsession with thinness and the implications of these new pharmaceutical interventions, raising questions about body image, health and the ongoing struggle against obesity.

Persons: Esther Dere, Nicole Rittenmeyer, Leah Varjacques, Dani Blum, Rachel Abrams, Oprah Winfrey, Elon Musk Organizations: Hulu Locations: America

☆ How RFK Jr's war on obesity in the age of Ozempic could shake up the booming weight-loss industry
▼ + stars: | 2024-11-19 | by ( Rebecca Torrence | Hilary Brueck | ) www.businessinsider.com time to read: +9 min

Robert F. Kennedy Jr.'s proposed appointment to lead the US Department of Health and Human Services could have big consequences for a booming weight-loss market. AdvertisementHis likely appointment comes at a pivotal moment for the weight-loss industry, as long-lasting shortages of drugs like Ozempic come to an end. When Farmbox launched in 2014 to deliver healthy food boxes and educate consumers about nutrition, "nobody wanted to invest in us," Tyrner-Dolce said. Doug Mills-Pool/Getty ImagesKennedy's crusade against Big Food could run up against Trump's pro-corporation agenda, though. AdvertisementWeight-loss companies could get more attention — at a costKennedy's focus on holistic chronic disease care, including obesity care, could see a renewed funding rush to the space.

Persons: Trump, Robert F, Kennedy Jr, Kennedy, he's, Obama, Ashley Tyrner, Dolce, Farmbox, FarmboxRx, Michelle Obama, SAUL LOEB, Kennedy's, Jeff Nobbs, Nobbs, Doug Mills, Elon Musk, Donald Trump Jr, podcaster Joe Polish, Brooke Boyarsky Pratt, There's, Knownwell Pratt, Pratt, John Stanford Organizations: Human Services, US Department of Health, National Institutes of Health, Food and Drug Administration, Trump, Big Pharma, Senate, Novo Nordisk, Centers, Medicare, Services, Getty, Street, Department of Health, US Department of Agriculture, Shack, Business, Big Food, Trump's, KFC, McDonald's, Fox, FDA, Moderna Locations: Pennsylvania, Washington

☆ 2 health stocks are buys. They've been beaten up enough on Trump's RFK Jr. pick for HHS
▼ + stars: | 2024-11-18 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Following Monday's trade, Jim Cramer's Charitable Trust will own 550 shares of DHR, increasing its weighting to roughly 3.6% from 3.4%. Since the election, Danaher shares have fallen from $250 each to $230 while Eli Lilly shares have dropped from $806 to $720. LLY YTD mountain Eli Lilly YTD Eli Lilly shares fell from $903 to $846 after a disappointing third-quarter report where inventory destocking of its fast-selling GLP-1 medications caused the company to miss estimates and lower full-year guidance. But the possible appointment of RFK Jr. has created a whole host of uncertainty for Eli Lilly and the drug stocks at large. If you look out to 2026, Lilly shares are trading at roughly 24 times.

Persons: Jim Cramer's, Donald Trump, Robert F, Kennedy Jr, We're, Danaher, Eli Lilly, Bioprocessing, Eli Lilly's, Lilly, Jim Cramer, Jim Organizations: DHR, Care Sector Fund, Department of Health, Human Services, RFK Jr, National Institutes of Health, HHS, CNBC Locations: Danaher

☆ Doctors say RFK Jr.’s anti-Ozempic stance perpetuates stigma and misrepresents evidence
▼ + stars: | 2024-11-17 | by ( Meg Tirrell | ) edition.cnn.com time to read: +9 min

Sanjay Gupta Reports: Is Ozempic Right For You?” at 8 p.m. Sunday, November 17, on CNN. Even as they agree that it’s important to address growing rates of diabetes and obesity, doctors in that field say Kennedy’s plans miss the mark. Not everyone with obesity will want the drugs, and for some, they may have strong side effects such as nausea. Doctors who treat people with obesity suggest that fixing the food system shouldn’t be mutually exclusive with using weight-loss medications, when appropriate. “But a lot of his thinking is like ‘A plus B plus C plus miracle, and you’ve got an answer.’”

Persons: Sanjay Gupta, Robert F, Kennedy Jr, Donald Trump’s, —, ” Kennedy, Greg Gutfeld, Kennedy, European Union “, Ozempic, ideation, Michael Osterholm, ” Osterholm, “, Trump, he’s, Kennedy’s, Josh Green, that’s, Kennedy —, ”, Jody Dushay, Dr, Angela Fitch, “ We’ve, ” Fitch, we’ve, ‘, ” Dr, Daniel Drucker, ” Drucker, don’t, they’re, Fitch, Doctors, Elon Musk, who’s, ” Musk, It’s, he’d, you’ve, ’ Organizations: CNN, US Department of Health, Human Services, Fox News, Novo Nordisk, Danish Medicines Agency, European Union, US Food and Drug Administration, Infectious Disease, University of Minnesota, FDA, US Centers for Disease Control, National Institutes of Health, Centers, Medicare, Services, HHS, Hawaii Gov, Environmental Protection Agency, BMI, Harvard Medical School, Beth Israel Deaconess Medical, Fox, CNN Health, NPR, Trump Locations: Denmark, America, Hawaii, Samoa

☆ Lost and found: Life after Ozempic and other weight-loss drugs was just the start for these four people
▼ + stars: | 2024-11-16 | by ( Carma Hassan | Zoe Todd | ) edition.cnn.com time to read: +19 min

The 22-year-old content creator approached her doctor about weight loss medication in March, before she had breast reduction surgery. Method: Zepbound, diet changes, exerciseZepbound, diet changes, exercise Duration: Took Zepbound from May to October. “The breast reduction was a big step, but the weight loss put a little cherry on top,” she said. Method: Compounded semaglutide, diet changes, exerciseCompounded semaglutide, diet changes, exercise Duration: Took compounded semaglutide from February to May. Method: Ozempic, diet changes, exerciseOzempic, diet changes, exercise Duration: Took Ozempic from May 2020 to October 2023“I was very close to being 300 pounds.

Persons: Sanjay Gupta, ”, Eduardo Grunvald, Alexus Murphy, CNN Alexus Murphy, Alexus, Murphy, It’s, it’s, “, ” Murphy, Alexus Murphy She’s, “ It’s, “ I’m, you’re, Steven Ray, Ray, he’s, ” Ray, Becky Bell, CNN Becky Bell, she’s, Bell, ” “, ” Ozempic, Max Nazaire, ” Bell, Nazaire, She’s, Ozempic, Dustin Gee, CNN Dustin Gee, didn’t, I’ve, –, ” Gee, Gee, ‘, Cristian, Emanuel, Jackson, Alex, Gee's, Dr, CNN’s Tal Yellin Organizations: CNN, CNN — Research, University of California, BMI, Houston, Inland, Health, Medi, Cal, US Food and Drug Administration, FDA, “, Bell, Ozempic, Mayo Clinic Diet, Get CNN, CNN Health Locations: San Diego, California, Houston, Woodstock , Georgia, Safe Haven, Peru, Bellingham , Massachusetts, Lima

☆ 5 new weight-loss drugs to watch in the fight for the next Ozempic
▼ + stars: | 2024-11-16 | by ( ) www.businessinsider.com time to read: +8 min

"Forthcoming medications take the blockbuster GLP-1 medications and up the ante." Like semaglutide (the active ingredient in Ozempic and Wegovy), it works on GLP-1, a hormone that regulates blood sugar and appetite. CagriSema adds it to the already-popular drug semaglutide, which itself helps manage hunger and blood sugar levels. "Longer-acting versions of GLP-1 medications offer the potential for greater convenience and potentially improved adherence and sustained use over time," McGowan said. Timeline: Data from Phase II trials is expected later this year, and planning is underway for Phase III trials.

Persons: Eli Lilly, Dr, Christopher McGowan, Eli Lilly's, Ozempic, retatrutide, VK2735, we've, they're, McGowan Organizations: Pharma, Novo Nordisk, Viking Therapeutics, Triple, Therapeutics, FDA, orforglipron, Nordisk, Reuters Locations: GLP, Mounjaro, California

☆ How we're thinking about Eli Lilly after Trump picked obesity-drug critic RFK Jr. to run HHS
▼ + stars: | 2024-11-15 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Shares of obesity drugmaker Eli Lilly fell more than 4% on Friday, extending a roughly 3% slide in Thursday's session. Ozempic is the posterchild of the fast-growing GLP-1 class, in which Novo Nordisk and Eli Lilly are currently the two dominant players. Bottom line Eli Lilly has been our favorite drug stock for years thanks to its stellar pipeline led by GLP-1s. But, at this point, Kennedy's nomination requires us to be more cautious on Eli Lilly in the near term. Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Persons: Eli Lilly, Donald Trump, Robert F, Kennedy Jr, Kentucky Sen, Rand Paul, Kennedy, Trump, Eli Lilly's, John F, Kennedy —, LLY, Eli Lilly's GLP, Jim Cramer, David Ricks, Lilly, It's, Jim, it's, Jim Cramer's, Cristina Arias Organizations: Republican, Department of Health, Human Services, HHS, and Drug Administration, Centers for Disease Control, Medicare, Medicaid, Senate, Democratic, GOP, Media, Novo Nordisk, Moderna, Pfizer, Deutsche Bank, GSK, White, CDC, Street Journal, GLP, Big Pharma, FDA, tirzepatide, CNBC, Company, Pharmaceutical Locations: Washington, Kentucky, Danish, U.S, Alcobendas, Madrid, Spain

☆ Blockbuster weight loss drugs are revealing what we still don’t understand about obesity
▼ + stars: | 2024-11-15 | by ( Dr. Sanjay Gupta | ) edition.cnn.com time to read: +10 min

Or any of the blockbuster weight loss and diabetes drugs that recently caught the world’s attention? The joy of foodHolst is also very focused on this particular mechanism of the GLP-1 drugs but worries that it can go too far. For others, it is the loss of lean muscle mass that accompanies their weight loss and puts them at greater risk for falls. Because the medications work by slowing digestion, terrible constipation becomes a side effect that is too much for some to bear. There is little doubt that for most people, regular exercise and eating right is still the best strategy for weight loss and overall health.

Persons: Sanjay Gupta, Jens Juul Holst, Holst, CNN Holst, Karin Conde, ” Conde, Knape, –, ”, Dr Organizations: CNN, Novo Nordisk, American Medical Association, World Health Organization, BMI, CNN Health Locations: Copenhagen, Danish, United States, “

Here's a rapid-fire update on all the stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. This time around, Trump's tariff proposals on Chinese imports could help Amazon in its competition against low-price online sellers Temu and Shein. Salesforce : Not a Trump stock, but it wasn't a Kamala Harris stock either. Constellation Brands : The Mexican beer importer has been punished on fears about what Trump's tariff and immigration proposals could do to its business. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, Jim, Donald Trump's, Trump's, Abbott, Trump, Hock Tan, Tan, We'll, it's pricier, Morgan Stanley, Wells, Kamala Harris, Agentforce, That's, Biden, Dover, Eaton's, Elon, Waymo, JD Vance, we've, Linde, that's, Eli Lilly, Robert F, Kennedy Jr, Kennedy, Lilly, Mark Zuckerberg, Zuckerberg, Goldman Sachs, shouldn't, Nextracker, Brian Niccol, Niccol, Stanley Black, Decker, TJ Maxx, Wells Fargo, Jim Cramer Organizations: Jim Cramer's Charitable Trust, CNBC, Abbott Laboratories, Abbott Labs, White, Biden, AMD, Trump, Wednesday, Broadcom, VMWare, BlackRock, Costco, Coterra Energy, Coterra, DuPont, Disney, GE Healthcare, GE Aerospace, Google, Honeywell, Elliott Investment Management, Linde, Microsoft, Big Tech, Apple, Meta, Financial Times, Nvidia, Palo Alto Networks, Yum Brands, Taco Bell, Constellation Brands, Management, TJX, Marshalls, Jim Cramer's Charitable Locations: China, India, Missouri, Wells Fargo, BlackRock, Shanghai, Dover, U.S, Palo, HomeGoods

☆ Philippe Laffont’s Coatue makes big bets on China and GLP-1 drugmakers in latest quarter
▼ + stars: | 2024-11-14 | by ( Pia Singh | In | ) www.cnbc.com time to read: +2 min

He also increased his stake in JD.com by 8.2 million shares, or 33,490%, and PDD Holdings by roughly 2.28 million shares, or 741%. Laffont also created new positions in iShares China Large-Cap ETF and KraneShares CSI China Internet ETF . Laffont also made a couple of significant increases to the fund's holdings in Eli Lilly and Novo Nordisk . Facebook parent Meta still remains the fund's largest holding, while Amazon, Microsoft and Nvidia remain in the fund's top 10. The filing also showed increased bets on Eaton Corporation, a name closely tied to the artificial intelligence-related energy infrastructure boom, as well as Constellation Energy and NextEra Energy .

Persons: Philippe Laffont's Coatue, Julian Robertson, Laffont, Donald Trump's, Xi Jinping, Eli Lilly Organizations: Philippe Laffont's Coatue Management, U.S . Securities, Exchange Commission, Tiger Management, PDD Holdings, KraneShares CSI China Internet, Novo Nordisk, Novo Nordisk's ADRs, Broadcom, Microsoft, Nvidia, chipmakers Qualcomm, Devices, Taiwan Semiconductor, Facebook, Amazon, Eaton Corporation, Constellation Energy, NextEra Energy Locations: Alibaba, JD.com, iShares China, China, Novo, chipmakers

☆ Ozempic and Wegovy may help curb alcohol addiction, study suggests
▼ + stars: | 2024-11-13 | by ( Kaitlin Sullivan | Kaitlin Sullivan Is A Contributor For Nbcnews.Com Who Has Worked With Nbc News Investigations. She Reports On Health | Science | ) www.nbcnews.com time to read: +5 min

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA Psychiatry suggests. Just over 28 million adults in the U.S. have alcohol addiction, according to the National Institute on Alcohol Abuse and Alcoholism. Several other studies have examined drinking habits among people taking GLP-1 drugs who do not have alcohol use disorder. Around 75,000 people in the study used some type of medication to treat alcohol use disorder. So far, the clearest results have come from studies on alcohol addiction — but there is still a lot to understand.

Persons: Ozempic, ”, Alex DiFeliceantonio, Markku, “, ” DiFeliceantonio, Christian Hendershot, Hendershot, Lähteenvuo, DiFeliceantonio, ” Hendershot Organizations: Psychiatry, National Institute, Alcohol, Biomedical Research Institute, Niuvanniemi Hospital, University of Southern California Institute for Addiction Science Locations: Sweden, U.S, Virginia, Finland, Swedish

☆ Amgen stock falls as analysts mull over weight loss drug’s bone density data
▼ + stars: | 2024-11-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Shares of Amgen fell more than 7% Tuesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. Amgen did not immediately respond to a request for comment on the dataThe drug is a promising potential competitor in the weight loss drug market. "On one hand, patients could naturally lose bone mineral density during weight loss treatment," Brayer wrote. But Brayer said, "on the other hand, this could be a non-starter because there seems to be a dose-dependent increase" in bone mineral density loss. Amgen is also aware of the "hypothetical concern" of bone mineral density loss, Yee said, citing the firm's discussions with management.

Persons: Amgen, Eli Lilly, Cantor Fitzgerald, Olivia Brayer, Eli, Wegovy, Brayer, Jefferies, Michael Yee, Yee, Evan Seigerman, hasn't, Seigerman Organizations: Novo Nordisk, BMO

☆ This Trump trade is an underappreciated opportunity, says Janus Henderson
▼ + stars: | 2024-11-12 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

Financial and energy stocks have jumped since last week's election, but there's another area of opportunity that investors could be missing out on, according to Janus Henderson. The market has rallied since President-elect Donald Trump' s victory, although it took a breather on Tuesday. However, financial stocks may have "gotten in a bit ahead of themselves," said Jeremiah Buckley, a portfolio manager at Janus Henderson. In addition, there is great research and development happening in health care right now, especially in health-care services, Buckley added. Among the funds Buckley oversees at Janus Henderson is the U.S. Dividend Income Fund .

Persons: Janus Henderson, Donald Trump, Jeremiah Buckley, Trump, Buckley, Eli Lilly, Amgen Organizations: Trump, P Health Care Services, UnitedHealth, Gilead Sciences

☆ Insulet CEO on earnings, GLP-1 and election impact
▼ + stars: | 2024-11-11 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailInsulet CEO on earnings, GLP-1 and election impactJim Hollingshead, Insulet CEO, joins 'Closing Bell: Overtime' to discuss the Insulet earnings, Apple blood sugar testing app and more.

Persons: Jim Hollingshead

☆ 'Today' host Al Roker says he doesn't judge anyone who uses Ozempic to lose weight
▼ + stars: | 2024-11-11 | by ( Amanda Goh | ) www.businessinsider.com time to read: +5 min

Al Roker, 70, says he won't judge people who use Ozempic and other medications for weight loss. I think everybody's journey is their journey," Roker told The Daily Mail. AdvertisementAl Roker, 70, says he doesn't want to judge anyone who uses Ozempic for weight loss. I think everybody's journey is their journey," Roker said. Roker has been open about his struggles with binge eating and his dramatic weight loss journey through the years.

Persons: Al Roker, Roker, —, you've, Ozempic, he's, everybody's, they've, Kelly Clarkson, Whoopi Goldberg, Clarkson, Elon Musk, Whoopi Goldberg —, Brianna Paruolo, Paruolo Organizations: Daily Mail, Service, Elon, FDA, Business Locations: New York

☆ Healthcare investors are torn on Trump's second term
▼ + stars: | 2024-11-09 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +11 min

While many tech VCs are optimistic about Trump's second term, some healthcare investors feel stuck. AdvertisementThe lower corporate taxes and deregulation a second Trump term could promise are already amplifying public market optimism. She could be removed as the FTC's head early in Trump's second term — and with relaxed M&A regulations, "anything is possible," said What If Ventures founder Stephen Hays. SOPA Images/Contributor/Getty ImagesMedicaid could also be targeted in Trump's second term. A boon for healthcare AI and Medicare AdvantageTrump's victory could have a positive impact on several big areas of healthcare investment.

Persons: —, Donald Trump's, Trump, He's, he'll, Robert F, Kennedy Jr, Trump's, Michael Greeley, Rebecca Noble, Tesla, JP Morgan Chase, Maven, Omada, Sean Duffy, Lina Khan, Stephen Hays, James Leynse, VCs, Carli Sapir, Jordan Nof, Greeley, Shiv Rao, Kennedy Jr's, Chrissy Farr, Phelps, Phillips, Farr Organizations: Trump, Service, Food and Drug Administration, Centers for Disease Control, Biden, Flare Capital Partners, Getty, Healthcare, Health, Cigna, Humana . Bloomberg, Federal Trade Commission, Investors, Business, Amboy Street Ventures, Tusk Venture, Senate, Affordable, Coalition for Health, Mayo Clinic, Johns Hopkins, Microsoft, Alignment Healthcare, Scrub Locations: Trump's Florida, Tuesday's, Trump's, Boston, America

☆ Watch CNBC's full interview with Novo Nordisk CEO Lars Fruergaard Jørgensen
▼ + stars: | 2024-11-07 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Novo Nordisk CEO Lars Fruergaard JørgensenLars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Money Movers' to discuss Jorgensen's comments on demand in 2025, if demand is waning for GLP-1 drugs, and much more.

Persons: Lars Fruergaard Jørgensen Lars Fruergaard Jørgensen Organizations: Novo Nordisk

☆ Novo Nordisk CEO on earnings: Very bullish on 2025 despite demand concerns
▼ + stars: | 2024-11-07 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk CEO on earnings: Very bullish on 2025 despite demand concernsLars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Money Movers' to discuss Jorgensen's comments on demand in 2025, if demand is waning for GLP-1 drugs, and much more.

Persons: Lars Fruergaard Jørgensen Organizations: Novo Nordisk

☆ Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
▼ + stars: | 2024-11-06 | by ( Sophie Kiderlin | In | ) www.cnbc.com time to read: +3 min

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance. The Danish pharmaceutical giant said that its net profit in the third quarter hit 27.3 billion Danish kroner ($3.92 billion), above an LSEG aggregate estimate of 26.95 billion Danish kroner. EBIT — earnings before tax and income — came to 33.8 billion Danish kroner, also just above the LSEG forecast of 33.51 billion Danish kroner. The guidance reflected the company's expectations for sales growth in North America and internationally, which is largely driven by volume growth of treatments based on Glucagon-like peptide-1 (GLP-1), Novo Nordisk said. Novo Nordisk added that it was investing in capacity both internally and externally to increase supply in the short- and long-term.

Persons: —, — CNBC's Annika Kim Constantino Organizations: Novo Nordisk, Wednesday, Novo, Nordisk, U.S . Food, Drug Administration Locations: Danish, North America, Novo, U.S

Search resuls for: "GLP"

25 mentions found